A preclinical study conducted by a team of scientists at the Institute for Bioengineering of Catalonia highlights the therapeutic potential of nanorobots in bladder cancer treatment.

Sangamo Therapeutics developed a novel capsid that achieved outstanding results in a preclinical study, this could have significant implications for treating neurological disorders.

With ongoing dose escalation and expansion, CRB-701 holds promise as a next-generation treatment for patients battling advanced cancers.

The microneedle drug delivery skin patch is made of hydrogel, making it cheap and sustainable to produce.

Serina Therapeutics licences their continuous drug delivery platform to Pfizer, which includes lipid nanoparticle delivery systems.

Advancements in Small Molecule Drug Formulation has witnessed remarkable progress in recent years including nanotechnology and new improved drug delivery systems.

Nanoparticles play a crucial role in tissue-targeted drug delivery, enabling the concentration of therapeutic agents at specific sites while minimising off-target events. Here, we explore some of their potential applications in drugging bone marrow and brain tissue.

The team is now working on commercializing the technology through their start-up PharLyfe+.

The sintering process in nanoscale 3D printing has paved the way for 4D printing, allowing devices printed in 3D to undergo transformational deformation in response to stimuli.

The collaboration will focus on RT-105, an orally administered biosimilar for adalimumab, an anti-inflammatory monoclonal antibody used to treat autoimmune diseases.

Work may provide insights to help improve treatment paradigm for retinal disorders.

Celanese to Supply VitalDose® Drug Delivery Platform for Glaukos’ Investigational iDose® TR Intraocular Implant.

Extensive experience with processes in sterile conditions.

New approaches to accelerating and refining the development of therapeutics are constantly being trialled across the globe. Here, we explore three different ways in which machine learning is being integrated into drug delivery and development.

The study found that faulty medical devices with potentially compromising shortcomings may still be valid as blueprints for future products, with more Class I recall events seen in 2022.

Our discussion group on new delivery technologies considered novel and imaginative techniques for delivering drugs to their active sites.

Key opinion leaders from AstraZeneca and King’s College London present their findings on cutting-edge approaches to nano delivery.

Liquid formulations of medicines exist to serve the needs of vulnerable patients. What are their applications? And what challenges are they facing, both in industry and on the market?

Using a combination of prevalent CSTDs with biologic molecules, we present a systematic approach to evaluate the risks and impact of CSTD to drug product quality, dose preparation, and dosing accuracy

June’s Formulation discussion group focusses on nanoparticle development, safety, and optimisation.

Tackling problems in cancer resistance by turning to using already approved drugs in new ways.

The blood-brain barrier is one of the greatest challenges in drug delivery. The complex issue of getting active molecules out of the blood and into the brain is a task that requires innovative solutions. We discuss some of those methods here.

Peptides and proteins present unique challenges in long-acting sustained drug delivery. How is MedinCell innovating within this field to achieve a customisable platform for long-acting injectable delivery?

Despite their advantages, combination products present new technological and organizational challenges. They require new product development strategies compared to standalone products, drugs, and devices.

Wicked problems – chronic health issues such as diabetes, obesity, and endocrine disorders – are projected to affect close to one billion people worldwide by 2045. By planning ahead and investing in digital healthcare solutions for connected drug delivery, companies such as Novo Nordisk are aiming to meet rising demands for the provision of healthcare as they occur.